Active Ingredient History
Sonidegib, also known as LDE225 and marketed as Odomzo, is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was approved by the FDA for treating basal cell carcinoma in July 2015 and is awaiting approval in the EU. The hedgehog pathway is involved in many human cancers. Sonidegib effectively inhibits the regulator called smoothened (Smo), preventing the hedgehog pathway from functioning. As a result, tumours that depend on the hedgehog pathway are unable to grow. Sonidegib is approved for use in the US and EU for treatment of adults with locally advanced basal cell carcinoma (BCC) that has recurred post surgery or radiation therapy. It is also approved for adult patients with BCC who are not eligible for surgery or radiation therapy. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Astrocytoma (Phase 1/Phase 2)
Basal Cell Nevus Syndrome (Phase 3)
Blood Coagulation Disorders (Phase 1/Phase 2)
Blood Platelet Disorders (Phase 1/Phase 2)
Bone Marrow Diseases (Phase 1/Phase 2)
Brain Neoplasms (Phase 1)
Breast Neoplasms (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Basal Cell (Phase 2/Phase 3)
Carcinoma, Hepatocellular (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Carcinoma, Transitional Cell (Phase 1)
Central Nervous System Neoplasms (Phase 1)
Choroid Plexus Neoplasms (Phase 1)
Colorectal Neoplasms (Phase 1)
Drug Evaluation (Phase 1)
Drugs, Investigational (Phase 1)
Ependymoma (Phase 1)
Esophageal Neoplasms (Phase 1)
Fibrosis (Phase 1)
Glioblastoma (Phase 1)
Glioma (Phase 1/Phase 2)
Graft vs Host Disease (Phase 1)
Hematologic Diseases (Phase 1/Phase 2)
Hemorrhagic Disorders (Phase 1/Phase 2)
Hepatoblastoma (Phase 1/Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 1)
Liver Diseases (Phase 1)
Lung Neoplasms (Phase 1)
Medulloblastoma (Phase 2)
Melanoma (Phase 1)
Meningioma (Phase 1)
Multiple Myeloma (Phase 2)
Myelodysplastic Syndromes (Phase 1)
Myeloproliferative Disorders (Phase 1/Phase 2)
Neoplasms ()
Neoplasms, Germ Cell and Embryonal (Phase 1)
Neoplasms, Neuroepithelial (Phase 1)
Neuroblastoma (Phase 1/Phase 2)
Neuroectodermal Tumors, Primitive (Phase 1)
Oligodendroglioma (Phase 1)
Ovarian Neoplasms (Phase 1)
Pancreatic Neoplasms (Phase 2)
Paraganglioma (Phase 1)
Pinealoma (Phase 1)
Polycythemia Vera (Phase 1/Phase 2)
Primary Myelofibrosis (Phase 1/Phase 2)
Prostatic Neoplasms (Phase 1)
Rhabdoid Tumor (Phase 1)
Rhabdomyosarcoma (Phase 1/Phase 2)
Safety (Phase 1)
Skin Neoplasms (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 1)
Stomach Neoplasms (Phase 1)
Thrombocythemia, Essential (Phase 1/Phase 2)
Thrombocytosis (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
